EA201891085A1 - Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания - Google Patents

Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания

Info

Publication number
EA201891085A1
EA201891085A1 EA201891085A EA201891085A EA201891085A1 EA 201891085 A1 EA201891085 A1 EA 201891085A1 EA 201891085 A EA201891085 A EA 201891085A EA 201891085 A EA201891085 A EA 201891085A EA 201891085 A1 EA201891085 A1 EA 201891085A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
ctc
heterogeneity
cells
characterize
Prior art date
Application number
EA201891085A
Other languages
English (en)
Russian (ru)
Inventor
Райан Диттамор
Дена Марринуччи
Original Assignee
Эпик Сайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпик Сайенсиз, Инк. filed Critical Эпик Сайенсиз, Инк.
Publication of EA201891085A1 publication Critical patent/EA201891085A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70589—CD45
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EA201891085A 2015-11-03 2016-11-01 Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания EA201891085A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250422P 2015-11-03 2015-11-03
PCT/US2016/059877 WO2017079139A1 (en) 2015-11-03 2016-11-01 Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity

Publications (1)

Publication Number Publication Date
EA201891085A1 true EA201891085A1 (ru) 2018-11-30

Family

ID=58662599

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891085A EA201891085A1 (ru) 2015-11-03 2016-11-01 Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания

Country Status (9)

Country Link
US (2) US20180321247A1 (ja)
EP (1) EP3371327A4 (ja)
JP (1) JP7043412B2 (ja)
CN (2) CN108603233A (ja)
AU (2) AU2016348401A1 (ja)
CA (1) CA3004150A1 (ja)
EA (1) EA201891085A1 (ja)
IL (1) IL259093A (ja)
WO (1) WO2017079139A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120276555A1 (en) 2009-10-21 2012-11-01 Peter Kuhn Method of Using Non-Rare Cells to Detect Rare Cells
EA201691496A1 (ru) 2014-01-27 2016-12-30 Эпик Сайенсиз, Инк. Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток
EP3108246B1 (en) 2014-02-21 2019-10-09 Epic Sciences, Inc. Methods for analyzing rare circulating cells
EP3948294B1 (en) * 2019-03-28 2023-06-07 Lundoch Diagnostics AB Use of follistatin in type 2 diabetes risk prediction
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9671405B2 (en) * 2012-09-19 2017-06-06 Cornell University Identifying taxane sensitivity in prostate cancer patients
CA2908745C (en) 2013-04-05 2023-03-14 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
EP3052940B1 (en) 2013-09-30 2021-05-26 The Scripps Research Institute Genotypic and phenotypic analysis of circulating tumor cells to monitor tumor evolution in prostate cancer patients
US20150147339A1 (en) * 2013-11-15 2015-05-28 Psma Development Company, Llc Biomarkers for psma targeted therapy for prostate cancer
US10745760B2 (en) 2014-01-17 2020-08-18 University Health Network Biopsy-driven genomic signature for prostate cancer prognosis
EA201691496A1 (ru) * 2014-01-27 2016-12-30 Эпик Сайенсиз, Инк. Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток
EP3100052B1 (en) * 2014-01-30 2021-03-10 Epic Sciences, Inc. Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies

Also Published As

Publication number Publication date
AU2016348401A1 (en) 2018-05-24
EP3371327A1 (en) 2018-09-12
CN115341033A (zh) 2022-11-15
US20210405055A1 (en) 2021-12-30
JP2018534595A (ja) 2018-11-22
IL259093A (en) 2018-06-28
JP7043412B2 (ja) 2022-03-29
CN108603233A (zh) 2018-09-28
US20180321247A1 (en) 2018-11-08
CA3004150A1 (en) 2017-05-11
EP3371327A4 (en) 2019-07-03
AU2023200364A1 (en) 2023-02-23
WO2017079139A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
EA201891571A1 (ru) Геномное профилирование отдельных циркулирующих опухолевых клеток (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания
EA201891085A1 (ru) Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания
EA201691505A1 (ru) Детектирование экспрессии простатического специфического мембранного антигена (psma) на циркулирующих опухолевых клетках (ctc)
EA201691352A1 (ru) Диагностика рака легкого с помощью циркулирующих опухолевых клеток
EA201691496A1 (ru) Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток
EA201792497A1 (ru) Антитела к gitr для диагностики злокачественной опухоли
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
EA201691499A1 (ru) Диагностика с помощью циркулирующих опухолевых клеток биомаркеров, позволяющих предсказывать резистентность по отношению к направленным на андрогеновый рецептор (ar) терапиям
MX361058B (es) Método para detectar células tumorales circulantes 5t4-positivas y métodos de diagnóstico de cáncer 5t4-positivo en un sujeto mamífero.
MX2015014474A (es) Dispositivo de recogida de fluidos biologicos y sistemas de recogida y ensayo de fluidos biologicos.
RU2013101996A (ru) Диагностика и лечение рака молочной железы
GB2545361A (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
WO2018183817A3 (en) Tumor burden as measured by cell free dna
MX2016012697A (es) Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales.
MX2018009254A (es) Metodos para evaluar el riesgo de desarrollar cancer colorrectal.
IL270974A (en) Methods for determining therapies based on single cell characterization of circulating cancer cells (CTC) in metastatic disease
EP3492607A3 (en) Urinary mirnas for the in vitro diagnosis of bladder cancer
EA201691168A1 (ru) Способы исследования бета-глюкана
EA201890816A1 (ru) Вариант 7as андрогенового рецептора как биомаркер для выбора лечения пациентов с метастатическим раком простаты, резистентным к кастрации (mcrpc)
BR102015015096A2 (pt) método de detecção in vitro de câncer de tireoide em um paciente, método in vitro de diferenciação entre câncer de tireoide e tecido de tireoide normal ou de lesões benignas de tireoide, uso de um conjunto de genes, método de obtenção de dados para direcionamento do tratamento do cancer de tireoide, kit laboratorial e dispositivo para classificar uma amostra biológica de glândula tireoide como maligna ou benigna
EA201690995A1 (ru) Способы обнаружения и количественного анализа циркулирующих эндотелиальных клеток
EA201992876A1 (ru) Способы определения терапии на основании характеристик отдельных клеток из циркулирующих опухолевых клеток (цок) при метастатическом заболевании
UA90720U (uk) Спосіб визначення генотоксичного впливу на клітини організму
PL415033A1 (pl) Sposób analizy białek w moczu
Zhang et al. Application and development of point-of-care testing in domain of tumor markers